HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Health OTC Drugs Innovation

How A UK Tech Start-Up Is Disrupting Men’s Health

  • Interviews

Executive Summary

HBW Insight talks to Numan's chief medical strategy officer Professor Sam Shah about how the UK tech start-up is bringing innovation to the country's men's health category. 

You may also be interested in...



Futura’s Revolutionary ED Treatment One Step Closer To US And EU OTC Approval

US and EU OTC approval for Futura's drug-free erectile dysfunction treatment MED3000 edges closer, following the company's submission of its EU dossier and a second pre-submission meeting with the FDA. 

EMA Approves EU-Wide Rx-to-OTC Switch Of Fortacin

Premature ejaculation treatment Fortacin is set to become only the fifth drug to achieve an Rx-to-OTC switch through EMA's centralized procedure, expanding the burgeoning OTC men's sexual health category. 

Pfizer's Upjohn Breaking The Silence Around ED With New Viagra Connect Campaign In UK

Pfizer is investing roughly $10m in Viagra Connect in the UK to help raise awareness of erectile problems among the country's male population. 

Table

View full table

Related Content

HBW Insight

Topics

Tags:
Health OTC Drugs Innovation
UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By